期刊
BREAST CANCER-BASIC AND CLINICAL RESEARCH
卷 9, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.4137/BCBCR.S29268
关键词
hormone receptor-positive; mTOR; everolimus; endocrine resistance
类别
资金
- Novartis Pharmaceuticals Corporation
The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor-positive, human epidermal growth factor receptor-negative metastatic disease that has progressed after prior endocrine therapy. This review summarizes findings from clinical trials that have demonstrated the benefit of everolimus in metastatic breast cancer and highlights some new research directions utilizing everolimus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据